Alexandria Real Estate Equities, Inc. is an S&P 500 company and a life science REIT founded in 1994 and incorporated in Maryland. The company pioneered the life science real estate niche and describes itself as the longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems. Its properties are located in life science and advanced technology innovation clusters including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City.
Alexandria Real Estate Equities Refinances With US$5 Billion Credit Facility
Alexandria Real Estate Equities and its operating partnership executed a Fourth Amended Credit Agreement on September 24, 2026, replacing their prior facility with a US$5.00 billion unsecured senior revolving credit line. The new facility includes an up to US$1.00 billion accordion feature, updated hybrid debt definitions, and an option to extend maturity to January 22, 2032. The agreement also removes automatic sustainability margin adjustments, a change that reshapes how the life science landlord manages funding, capital recycling, and balance sheet repair. The expanded credit line ties most directly into Alexandria's ongoing US$2.9 billion capital recycling and joint venture program, supporting asset sales, joint venture structuring, and project funding flexibility. The company's narrative projects US$2.5 billion in revenue and US$278.8 million in earnings by 2029, with a fair value estimate of US$52.57, an 11% upside to its current price.
ARE · Capital · Positive Alexandria executed a new US$5.00 billion unsecured revolving credit facility with a US$1.00 billion accordion and extended maturity, strengthening its funding and balance-sheet flexibility.
Baron Real Estate Income Fund Buys Alexandria Real Estate Equities Stake in Q2 2026
Baron Capital's Baron Real Estate Income Fund acquired a new position in Alexandria Real Estate Equities, Inc. in the second quarter of 2026, according to the fund's Q2 2026 investor letter. The life science REIT accounted for 4.0% of the Fund's assets as of quarter end, with the fund citing signs that life science real estate fundamentals are beginning to stabilize after several years of weak demand, excess supply deliveries, and a rising cost of capital. The Fund gained 12.18% on Institutional Shares in the quarter, modestly outperforming the MSCI US REIT Index, which rose 11.84%, and Morningstar ranks it the #2 real estate fund since its December 2017 inception. Alexandria closed at $53.52 per share on September 16, 2026, with a one-month return of 5.70% and a 52-week loss of 36.01%, a market capitalization of $9.33 billion, and a 52-week trading range between $39.41 and $88.24. Baron said it expects Alexandria's growth to inflect positively over the next couple of years while the company sells select properties and accretively recycles capital into share repurchases.
ARE · Capital · Positive Baron Real Estate Income Fund disclosed a new Q2 2026 stake in Alexandria, citing stabilizing life science fundamentals and expected positive growth inflection with property sales recycled into buybacks.
Baron Capital · · Neutral Baron Capital is the fund manager whose Q2 2026 letter and new Alexandria position are reported, but the article gives no independent development affecting Baron itself.
Alexandria Real Estate Equities reported a narrower second-quarter net loss of $0.43 per share, swinging to a first-half profit of $1.68 per share, but its funds from operations fell sharply, with adjusted FFO per share dropping to $1.73 in Q2 from $2.33 a year earlier. Leasing activity surged 60% quarter-over-quarter to over 1 million square feet, yet same-property net operating income declined 10.6% and operating occupancy slipped to 86.9%. The company maintains $3.6 billion in liquidity and extended its credit line to 2032 at a lower rate, but leverage stands at 7.0x net debt to EBITDA, above its 4Q target of 5.6x to 6.2x, which depends on completing $2.9 billion in dispositions. Management kept its dividend at $0.72 per share and reaffirmed 2026 FFO guidance at a $6.40 midpoint, while recording $222.5 million in impairment charges.
ARE · Capital · Negative Adjusted FFO per share dropped to $1.73 from $2.33, same-property NOI declined 10.6%, and leverage is high at 7.0x net debt to EBITDA.
Alexandria Real Estate Equities prices $1B notes offering
Alexandria Real Estate Equities priced a $1 billion offering of 7.25% Series A fixed-to-fixed reset rate junior subordinated notes due 2057. The notes were priced at 100.000% of the principal amount and will pay 7.25% annual interest through, but excluding, February 2032. After that, the rate will reset every five years to the five-year U.S. Treasury rate plus 2.889%, with a minimum rate of 7.25%. The company plans to use the net proceeds for general corporate purposes.
Alexandria Real Estate Q2 Loss Narrows to $73.7 Million
Alexandria Real Estate Equities reported a narrower second-quarter net loss. The life science-focused REIT posted a net loss attributable to common stockholders of $73.7 million, or $0.43 per share, compared with a loss of $109.6 million, or $0.64 per diluted share, a year earlier. Adjusted funds from operations attributable to common stockholders fell to $296.1 million, or $1.73 per share, from $396.4 million, or $2.33 per share. Total revenue decreased to $662.8 million from $762.0 million, with rental income declining to $643.2 million from $737.3 million. The company tightened its fiscal 2026 adjusted FFO guidance to a range of $6.35 to $6.45 per share, maintaining the midpoint at $6.40.
Alexandria Real Estate Equities beats Q2 FFO and revenue estimates
Alexandria Real Estate Equities reported second-quarter funds from operations of $1.73 per share, topping the Zacks Consensus Estimate of $1.65 per share by 4.85%. Revenue came in at $662.78 million, surpassing the consensus forecast by 2.12%. The company has beaten FFO estimates twice in the past four quarters and exceeded revenue expectations three times over the same period. Shares have gained about 5.1% year to date, trailing the S&P 500's 9.4% advance.
Alexandria Real Estate Equities delivers 427,000 RSF R&D hub for Bristol Myers Squibb in San Diego
Alexandria Real Estate Equities has delivered a 427,000 RSF research and development facility for Bristol Myers Squibb at its San Diego megacampus. The new state-of-the-art R&D hub marks an operational milestone for the company and reflects demand from a large multinational pharmaceutical tenant. Alexandria Real Estate Equities focuses on life science and R&D campuses that serve large pharmaceutical and biotech companies, and this project adds scale to its megacampus model. The facility illustrates how purpose-built lab and R&D space can sit at the center of long-term relationships with global drug developers. For investors, the Bristol Myers Squibb hub may serve as a reference point for how fully built-out campuses can support leasing, development activity, and tenant retention.
United States